Editorial Volume 14, Issue 14 pp 5612—5613
Metformin and breast cancer: an opportunity for pharmacogenetics
Figure 1. The C allele of the rs11212617 SNV: a pharmacogenetic biomarker of response to metformin at the interface of T2D and HER2+ breast cancer. rs1121261 should be explored in prospective trials as a pharmacogenomic profiling system to individualized metformin therapy for breast cancer patients. (Abbreviations: T2D: type 2 diabetes; BC: breast cancer; pCR: pathological complete response; IDFS: invasive disease-free survival; OS: overall survival). Created with https://Biorender.com.